Cell Therapy Market to Top $20 Billion by 2030 as BioAge Labs Advances Anti-Aging Research
BIOA•Global cell therapy market valued at $4.7 billion in 2023 is projected to exceed $20 billion by 2030, driven by stem cells, regenerative biologics and senolytic treatments. BioAge Labs is among leading biotech firms exploring cell-based approaches targeting anti-aging and neurodegenerative diseases.
1. Market Growth and Projections
The global cell therapy sector was valued at $4.7 billion in 2023 and is forecast to surpass $20 billion by 2030. This surge is propelled by investments in stem cell platforms, regenerative biologics and senolytic treatments aimed at tissue repair and inflammation reduction.
2. BioAge Labs’ Strategic Position
BioAge Labs is identified among several biotech firms entering cell-based anti-aging and neurodegeneration segments. The company’s research focus includes precision biologics designed to restore tissue function and potentially reverse damage tied to aging and chronic disease.
3. Neurodegenerative and Senolytic Market Opportunities
Analysts predict the senolytics and anti-aging pharmaceuticals market will reach $6.39 billion by 2030, while the broader neurodegenerative treatment market could grow from $58.4 billion in 2025 to $85 billion by 2032. These expanding niches underscore the potential for disease-modifying, cell-based therapies.
